Expression and clinical significance of reps2 in human esophageal squamous cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 2851-2857

  Zhang, Hang ^a   Duan, Chao Jun ^a   Zhang, Heng ^a   Cheng, Yuan Da ^a   Zhang, Chun Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinicopathology; Esophageal squamous cell carcinoma; Metastasis; Prognosis; REPS2

Indexed keywords

MESSENGER RNA; REPS2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; BIOSYNTHESIS; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DOWN REGULATION; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; AGED; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84880357934     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.2851     Document Type: Article

References (25)

1. Badway JA, Baleja JD (2011). Reps2: a cellular signaling and molecular trafficking nexus. Int J Biochem Cell Biol, 43, 1660-3.
2. Bashir M, Kirmani D, Bhat HF, et al (2010). P66shc and its downstream Eps8 and Rac1 proteins are upregulated in esophageal cancers. Cell Commun Signal, 8, 13.
3. Chai J, Jamal MM (2012). Esophageal malignancy: A growing concern. World J Gastroenterol, 18, 6521-6.
4. Chang GT, Blok LJ, Steenbeek M, et al (1997). Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res, 57, 4075-81.
5. Chen H, Fre S, Slepnev VI, et al (1998). Epsin is an EH-domainbinding protein implicated in clathrin-mediated endocytosis. Nature, 394, 793-7.
6. Chen SB, Weng HR, Wang G, et al (2013). Prognostic factors and outcome for patients with esophageal squamous cell carcinoma underwent surgical resection alone: evaluation of the seventh edition of the american joint committee on cancer staging system for esophageal squamous cell carcinoma. J Thorac Oncol, 8, 495-501.
7. Doolan P, Clynes M, Kennedy S, et al (2009). TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer. Tumour Biol, 30, 200-9.
8. Feng JG, Liu Q, Qin X, et al (2012). Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas. Mol Biol Rep, 39, 1267-74.
9. Ikeda M, Ishida O, Hinoi T, et al (1998). Identification and characterization of a novel protein interacting with Ralbinding protein 1, a putative effector protein of Ral. J Biol Chem, 273, 814-21.
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Joneson T, Bar-Sagi D (1999). Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol, 19, 5892-901.
12. Jullien-Flores V, Dorseuil O, Romero F, et al (1995). Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem, 270, 22473-77.
13. Kariya K, Koyama S, Nakashima S, et al (2000). Regulation of complex formation of POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation. J Biol Chem, 275, 18399-406.
14. Loudig O, Brandwein-Gensler M, Kim RS, et al (2011). Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma. Hum Pathol, 42, 1911-22.
15. Morinaka K, Koyama S, Nakashima S, et al (1999). Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. Oncogene, 18, 5915-22.
16. Nakashima S, Morinaka K, Koyama S, et al (1999). Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors. EMBO J, 18, 3629-42.
17. OosterhoffJK, Kuhne LC, Grootegoed JA, Blok LJ (2005). EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer, 113, 561-7.
18. OosterhoffJK, Penninkhof F, Brinkmann AO, et al (2003). REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene, 22, 2920-25.
19. Oshiro T, Koyama S, Sugiyama S, et al (2002). Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration. J Biol Chem, 277, 38618-26.
20. Penninkhof F, Grootegoed JA, Blok LJ (2004). Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene, 23, 5607-15.
21. Rincon SA, Ye Y, Villar-Tajadura MA, et al (2009). Pob1 participates in the Cdc42 regulation of fission yeast actin cytoskeleton. Mol Biol Cell, 20, 4390-9.
22. Rodriguez-Rocha H, Garcia Garcia A, Zavala-Flores L, et al (2012). Glutaredoxin 1 protects dopaminergic cells by increased protein glutathionylation in experimental Parkinson's disease. Antioxid Redox Signal, 17, 1676-93.
23. Singhal SS, Yadav S, Drake K, et al (2008). Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem, 283, 19714-29.
24. Tomassi L, Costantini A, Corallino S, et al (2008). The central proline rich region of POB1/REPS2 plays a regulatory role in epidermal growth factor receptor endocytosis by binding to 14-3-3 and SH3 domain-containing proteins. BMC Biochem, 9, 21.
25. Toya M, Iino Y, Yamamoto M (1999). Fission yeast Pob1p, which is homologous to budding yeast Boi proteins and exhibits subcellular localization close to actin patches, is essential for cell elongation and separation. Mol Biol Cell, 10, 2745-57.